Zhao Wen, Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Wang Yunfei, Song Yanan, Jisheng Li. "Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced
                    <i>EGFR</i>
                    -mutant NSCLC in the US and China.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e23169